Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show

ALX Oncology to Present ALX148 Phase 1 Study at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting


ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that the Phase 1 study of ALX148 in patients with advanced solid tumors has been selected for presentation in the Poster Discussion Session at the Virtual 2020 ASCO Annual Meeting, May 29 ? 31, 2020.

Virtual ASCO 2020 Presentation Information
Title: A Phase 1 study of ALX148, a CD47 blocker, in combination with standard anticancer antibodies and chemotherapy regimens in patients with advanced malignancy (Abstract #3056).
Poster Discussion Session: Developmental Therapeutics?Immunotherapy
Date: Friday, May 29

About ALX Oncology

ALX Oncology is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology's lead product candidate, ALX148, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated proprietary Fc domain. ALX148 has demonstrated promising clinical activity across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to advance ALX148 into clinical development for the treatment of myelodysplastic syndromes and to continue clinical development for the treatment of a range of solid tumor indications.


These press releases may also interest you

at 10:19
Revvity's EUROIMMUN and ALPCO-GeneProof Announce Strategic Partnership to Expand CE-IVD Molecular Assay Offerings
Revvity's EUROIMMUN business, a leading provider of high-quality in-vitro diagnostic products, and ALPCO-GeneProof, a global leader in molecular diagnostics, jointly announced a strategic partnership to enhance the availability of GeneProof PCR kits...

at 10:17
Fx Chocolate®, a Designs for Health Brand, Launches Yes Whey!!!tm Chocolate Supplement Bar to Elevate the Mainstream Protein Bar Space
Fx Chocolate®, a Designs for Health brand that provides functional amounts of high-quality supplements in handcrafted chocolate, today announced the launch of its Yes Whey!!!tm chocolate supplement bar. Yes Whey!!!tm harnesses 15 grams of...

at 10:16
Varian Collaborates with BaraSeen Medical Company to Pave the Way for Advanced Cancer Treatment in Saudi Arabia with Sustainable Halcyon Technology
Varian, a Siemens Healthineers Company, announces its collaboration with BaraSeen Medical Company to introduce the first Halcyon system in Saudi Arabia - with its hallmark sustainability features - at BaraSeen's initial specialized standalone Batik-X...

at 10:15
Upholding their Oath: Veterinarians Balance Purpose with Practicality
From the childhood dream of becoming a veterinarian and saving the lives of pets, to today's realities of practicing veterinary medicine, the deep commitment veterinarians feel for their calling remains unchanged. However, certain factors make that...

at 10:12
Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference
Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that results from the ibezapolstat Phase 2 clinical...

at 10:02
Completion of Largest Capacity GMP Run Marks New Standard in Biologics Manufacturing
Boston Institute of Biotechnology, LLC (BIB) in collaboration with BIBo-Biopharma, proudly announces the successful completion of a groundbreaking 30,000L fermentation run, marking a significant milestone in biotechnology history....

More news about Health...


News published on and distributed by: